Permethrin
Pyrethrines, Incl. Synthetic Compounds
- Drug class
- Pyrethrines, Incl. Synthetic Compounds
- Availability
- Prescription and OTC
- Routes
- Topical
- Markets covered
- 3
- Products on record
- 11
- FDA reports (12 mo)
- 78
Overview
Plain-language summary, compiled from the cited regulatory records
Permethrin is a synthetic pyrethroid insecticide [1]. It belongs to the drug class of Pyrethrins, Including Synthetic Compounds (P03AC) [1]. Permethrin is approved for the treatment of head lice [1].
In the past 12 months, there have been 78 adverse event reports associated with permethrin [2]. Among the most frequently reported reactions were "Drug Ineffective," "Product Use In Unapproved Indication," "Pruritus," "Drug Ineffective For Unapproved Indication," and "Nausea" [2]. Permethrin is available under various brand names in the market [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | May 15, 2026 |
| CA Canada | Health Canada | 4 | March 22, 2025 |
| US United States | FDA | 3 | March 4, 2026 |
GBUnited Kingdom· MHRA
4 products
Uses
Permethrin Cream is indicated for the treatment of scabies in adults and children aged from 2 months, and crab lice in adults.
How to take
CACanada· Health Canada
4 products
Uses
, 4 DOSAGE AND ADMINISTRATION 01/2022 TABLE OF CONTENTS RECENT MAJOR LABEL CHANGES............................................................................................ 2 TABLE OF CONTENTS ..............................................................................................................
2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS ..............................................................................................................
1 Pediatrics .......................................................................................................... 2 Geriatrics...........................................................................................................
4 2 CONTRAINDICATIONS ................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 4 4 DOSAGE AND ADMINISTRATION.................................................................................
USUnited States· FDA
3 products
Uses
Use treats head lice
How to take
Sources & citations
- [1]MHRA (UK) · PL201170361 · revised March 6, 2026
- [2]Health Canada (DPD) · 00771368 · revised March 22, 2025
- [3]FDA DailyMed · 056fb377-34dd-4d… · revised November 21, 2022 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.